- Home
- EDIT vs BCV Comparison
EDIT vs BCV Comparison
Compare EDIT & BCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- BCV
- Stock Information
- Founded
- EDIT 2013
- BCV 1971
- Country
- EDIT United States
- BCV United States
- Employees
- EDIT N/A
- BCV N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- BCV Finance/Investors Services
- Sector
- EDIT Health Care
- BCV Finance
- Exchange
- EDIT Nasdaq
- BCV Nasdaq
- Market Cap
- EDIT 108.1M
- BCV 103.0M
- IPO Year
- EDIT 2016
- BCV N/A
- Fundamental
- Price
- EDIT $1.25
- BCV $17.31
- Analyst Decision
- EDIT Buy
- BCV
- Analyst Count
- EDIT 14
- BCV 0
- Target Price
- EDIT $8.08
- BCV N/A
- AVG Volume (30 Days)
- EDIT 2.5M
- BCV 26.3K
- Earning Date
- EDIT 03-05-2025
- BCV 01-01-0001
- Dividend Yield
- EDIT N/A
- BCV 8.13%
- EPS Growth
- EDIT N/A
- BCV N/A
- EPS
- EDIT N/A
- BCV N/A
- Revenue
- EDIT $32,314,000.00
- BCV N/A
- Revenue This Year
- EDIT N/A
- BCV N/A
- Revenue Next Year
- EDIT N/A
- BCV N/A
- P/E Ratio
- EDIT N/A
- BCV N/A
- Revenue Growth
- EDIT N/A
- BCV N/A
- 52 Week Low
- EDIT $1.12
- BCV $14.09
- 52 Week High
- EDIT $7.41
- BCV $18.11
- Technical
- Relative Strength Index (RSI)
- EDIT 41.70
- BCV 33.45
- Support Level
- EDIT $1.24
- BCV $17.37
- Resistance Level
- EDIT $1.32
- BCV $18.20
- Average True Range (ATR)
- EDIT 0.11
- BCV 0.26
- MACD
- EDIT -0.03
- BCV -0.02
- Stochastic Oscillator
- EDIT 2.94
- BCV 0.00
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.